These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 8646800

  • 21. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
    O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen TL, Sartorius S, Bowling K, Smith J, Brubaker A, Lubejko B, Ignacio V, Grochow LB.
    J Natl Cancer Inst; 1996 Jun 19; 88(12):817-24. PubMed ID: 8637048
    [Abstract] [Full Text] [Related]

  • 22. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
    Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF.
    Cancer Chemother Pharmacol; 1999 Jun 19; 43(6):454-60. PubMed ID: 10321504
    [Abstract] [Full Text] [Related]

  • 23. Limited sampling models for topotecan pharmacokinetics.
    van Warmerdam LJ, Verweij J, Rosing H, Schellens JH, Maes RA, Beijnen JH.
    Ann Oncol; 1994 Mar 19; 5(3):259-64. PubMed ID: 8186175
    [Abstract] [Full Text] [Related]

  • 24. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
    Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG.
    Cancer Res; 1993 Feb 15; 53(4):725-7. PubMed ID: 8428353
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN.
    Clin Cancer Res; 1996 Sep 15; 2(9):1489-97. PubMed ID: 9816325
    [Abstract] [Full Text] [Related]

  • 27. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C.
    Oncology; 1999 Sep 15; 56(1):1-12. PubMed ID: 9885371
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
    Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP, Borad MJ, Fitch TR, Northfelt DW.
    J Clin Pharmacol; 2010 Mar 15; 50(3):268-75. PubMed ID: 19808951
    [Abstract] [Full Text] [Related]

  • 31. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
    Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verweij J.
    Br J Cancer; 1996 May 15; 73(10):1268-71. PubMed ID: 8630291
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
    Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ.
    J Clin Oncol; 1998 Mar 15; 16(3):1122-30. PubMed ID: 9508199
    [Abstract] [Full Text] [Related]

  • 34. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL.
    Gynecol Oncol; 2000 Aug 15; 78(2):228-34. PubMed ID: 10926808
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
    Gerrits CJ, Creemers GJ, Schellens JH, Wissel P, Planting AS, Kunka R, Selinger K, de Boer-Dennert M, Marijnen Y, Harteveld M, Verweij J.
    Br J Cancer; 1996 Mar 15; 73(6):744-50. PubMed ID: 8611374
    [Abstract] [Full Text] [Related]

  • 37. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
    Herben VM, ten Bokkel Huinink WW, Schot ME, Hudson I, Beijnen JH.
    Anticancer Drugs; 1998 Jun 15; 9(5):411-8. PubMed ID: 9660538
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW.
    Clin Cancer Res; 1998 Feb 15; 4(2):317-24. PubMed ID: 9516917
    [Abstract] [Full Text] [Related]

  • 40. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD.
    Anticancer Drugs; 1994 Aug 15; 5(4):394-402. PubMed ID: 7949242
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.